Partnering with MIND Foundation offers a unique opportunity to drive important research and implement innovative programs in mental health and human development.
Our commitment to scientific rigor and ethical standards drives impactful solutions, making us a trusted leader in the field of psychedelic research and therapies. By collaborating with us, you contribute to pioneering studies and join a network dedicated to enhancing mental health care across Europe and beyond. Together, we can transform lives, influence public health policies, and shape the future of mental wellness.
Join us in making a meaningful difference through research, education, and community engagement.
In the MIND Foundation, we distinguish between two general kinds of partnerships which we may develop further into different sub-types.
OVID Clinic Berlin is Europe’s first mental health provider integrating psychedelic therapies into a guideline-based outpatient and day clinic model. Founded in 2021, OVID is a cornerstone of the MIND Foundation ecosystem. While it operates as an independent entity, OVID closely aligns with MIND’s mission and values.
OVID Clinic Berlin targets diverse patient needs and groups with guideline therapies and psychedelic treatments. Our collaboration ensures that our patients benefit from the latest scientific advancements in psychedelic therapies, while adhering to the highest standards of clinical practice.
Together, MIND and OVID are transforming the landscape of mental health care, paving the way for more effective, accessible, and holistic treatment options.
Along with the Central Institute of Mental Health in Mannheim and the Department of Psychiatry and Psychotherapy at Charité Universitätsmedizin Berlin, we are a partner in what is currently the largest science-initiated psilocybin study in the world. The study is funded by the German Federal Ministry of Education and Research (BMBF).
This phase 2b clinical trial is called EPIsoDE. It is investigating the safety and efficacy of psilocybin in the treatment of patients with treatment-resistant depression. There are two centers in Mannheim and Berlin.
Data readout expected in Q3 2024.
MIND Newsletter